BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28781274)

  • 1. [A novel prognostic model incorporating genetic profiling for myelodysplastic syndromes].
    Nagata Y; Ogawa S
    Rinsho Ketsueki; 2017; 58(7):776-786. PubMed ID: 28781274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.
    Haferlach T; Nagata Y; Grossmann V; Okuno Y; Bacher U; Nagae G; Schnittger S; Sanada M; Kon A; Alpermann T; Yoshida K; Roller A; Nadarajah N; Shiraishi Y; Shiozawa Y; Chiba K; Tanaka H; Koeffler HP; Klein HU; Dugas M; Aburatani H; Kohlmann A; Miyano S; Haferlach C; Kern W; Ogawa S
    Leukemia; 2014 Feb; 28(2):241-7. PubMed ID: 24220272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
    Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
    Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
    Itzykson R; Kosmider O; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of myelodysplastic syndromes (MDS): An update.
    Ganguly BB; Kadam NN
    Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive analysis of genetic factors predicting overall survival in Myelodysplastic syndromes.
    Maurya N; Mohanty P; Dhangar S; Panchal P; Jijina F; Mathan SLP; Shanmukhaiah C; Madkaikar M; Vundinti BR
    Sci Rep; 2022 Apr; 12(1):5925. PubMed ID: 35396491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R.
    Tefferi A; Lasho TL; Patnaik MM; Saeed L; Mudireddy M; Idossa D; Finke C; Ketterling RP; Pardanani A; Gangat N
    Am J Hematol; 2017 Dec; 92(12):1311-1317. PubMed ID: 28875545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
    Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
    Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A; Boultwood J
    Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes.
    Duncavage EJ; Tandon B
    Int J Lab Hematol; 2015 May; 37 Suppl 1():115-21. PubMed ID: 25976969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromothripsis Is a Recurrent Genomic Abnormality in High-Risk Myelodysplastic Syndromes.
    Abáigar M; Robledo C; Benito R; Ramos F; Díez-Campelo M; Hermosín L; Sánchez-Del-Real J; Alonso JM; Cuello R; Megido M; Rodríguez JN; Martín-Núñez G; Aguilar C; Vargas M; Martín AA; García JL; Kohlmann A; Del Cañizo MC; Hernández-Rivas JM
    PLoS One; 2016; 11(10):e0164370. PubMed ID: 27741277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excellent Prognosis of Low-Risk Myelodysplastic Syndromes (MDS) Without Detectable Myeloid-Related Mutations.
    Polprasert C; Niparuck P; Rattanathammethee T; Chuncharunee S; Kobbuaklee S; Songserm K; Suksusut A; Trithiphen S; Lanamtieng T; Kongkiatkamon S; Chanswangphuwana C; Lawasut P; Bunworasate U; Rojnuckarin P
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e293-e299. PubMed ID: 34840089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine clinical mutation profiling using next generation sequencing and a customized gene panel improves diagnostic precision in myeloid neoplasms.
    Bartels S; Schipper E; Hasemeier B; Kreipe H; Lehmann U
    Oncotarget; 2016 May; 7(21):30084-93. PubMed ID: 27029036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular Markers of Prognosis in Myelodysplastic Syndromes--Review].
    Xu YY; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):285-9. PubMed ID: 26913438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes.
    Yang X; Zhao H; Wu H; Guo X; Jia H; Liu W; Wei Y; Can C; Ma D
    Clin Chim Acta; 2024 Feb; 554():117789. PubMed ID: 38246208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations and prognosis in myelodysplastic syndromes: karyotype-adjusted analysis of targeted sequencing in 300 consecutive cases and development of a genetic risk model.
    Gangat N; Mudireddy M; Lasho TL; Finke CM; Nicolosi M; Szuber N; Patnaik MM; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
    Am J Hematol; 2018 May; 93(5):691-697. PubMed ID: 29417633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
    Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
    J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.
    Nazha A; Bejar R
    Curr Hematol Malig Rep; 2017 Oct; 12(5):461-467. PubMed ID: 28844082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms.
    Patel B; Hirsch C; Clemente M; Sekeres M; Makishima H; Maciejewski JP
    Int J Hematol; 2015 Mar; 101(3):213-8. PubMed ID: 25690487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes.
    Meggendorfer M; Haferlach C; Kern W; Haferlach T
    Haematologica; 2017 Sep; 102(9):1502-1510. PubMed ID: 28642303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.